GlassScriptPhysician profile
Lindsay M Sheets
NPI 1710446497
$8,313.81
in general payments reported to CMS, 2019-2025
34 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,344 · 2022: $2,673 · 2023: $1,719 · 2024: $450 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683 · Travel and Lodging: $601 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.19 |
| Travel and Lodging | $601.31 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,561.51 | 2021-2023 | Fasenra, Tezspire, Symbicort |
| Inspire Medical Systems, INC. | $1,052.47 | 2021-2024 | Inspire |
| Glaxosmithkline, LLC. | $850.98 | 2021-2023 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $700.20 | 2021-2023 | Ofev |
| Jazz Pharmaceuticals INC. | $376.95 | 2021-2023 | |
| Genzyme Corporation | $332.68 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.47 | 2021-2023 | Glassia |
| Electromed, INC. | $311.12 | 2021-2023 | Smartvest |
| Mylan Specialty L.P. | $292.22 | 2021-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $265.21 | 2021-2023 | Opsumit, Uptravi |
| Idorsia Pharmaceuticals US INC | $264.75 | 2023-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $252.80 | 2021-2023 | Dupixent |
| Axsome Therapeutics, INC. | $208.00 | 2022-2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $158.55 | 2021-2023 | |
| Philips North America LLC | $145.00 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $131.18 | 2022-2025 | Wakix |
| Optinose US, INC. | $126.25 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $113.08 | 2021-2023 | Nuzyra |
| United Therapeutics Corporation | $111.91 | 2021-2023 | Tyvaso |
| Inogen, INC. | $102.04 | 2022-2023 | Inogen |
| Amgen INC. | $98.70 | 2021-2022 | |
| Genentech USA, INC. | $92.56 | 2022 | |
| Kaleo, INC. | $85.06 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $82.52 | 2023-2025 | Lumryz |
| Csl Behring | $66.39 | 2021-2022 | |
| Insmed, INC. | $52.25 | 2022 | |
| Mallinckrodt Hospital Products INC. | $38.08 | 2021-2022 | |
| Baxter Healthcare | $26.82 | 2022 | |
| Grifols USA, LLC | $24.13 | 2022 | |
| Lilly USA, LLC | $16.91 | 2025 | Zepbound |
| Pulmonx Corporation | $15.70 | 2021 | |
| Merck Sharp & Dohme LLC | $14.94 | 2022 | |
| Novo Nordisk INC | $14.67 | 2025 | |
| Azurity Pharmaceuticals, INC. | $13.71 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.